Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M

ZEVRA THERAPEUTICS, INC.

9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.
Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.
Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.
Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.